Sage Therap Drug Patent Portfolio
Sage Therap owns 1 orange book drug protected by 8 US patents Given below is the list of Sage Therap's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US10940156 | Neuroactive steroids, compositions, and uses thereof | 08 Mar, 2037 | Active |
| US10251894 | Anticonvulsant activity of steroids | 27 Nov, 2033 | Active |
| US10322139 | Neuroactive steroid formulations and methods of treating CNS disorders | 23 Jan, 2033 | Active |
| US10117951 | Sulfoalkyl ether cyclodextrin compositions | 13 Mar, 2029 | Active |
| US7635773 | Sulfoalkyl ether cyclodextrin compositions | 13 Mar, 2029 | Active |
| US8410077 | Sulfoalkyl ether cyclodextrin compositions | 13 Mar, 2029 | Active |
| US9200088 | Sulfoalkyl ether cyclodextrin compositions | 13 Mar, 2029 | Active |
| US9750822 | Sulfoalkyl ether cyclodextrin compositions | 13 Mar, 2029 | Active |
Latest Legal Activities on Sage Therap's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Sage Therap.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 4th Year, Large Entity | 30 Nov, 2022 | US10322139 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 21 Sep, 2022 | US10251894 |
|
Recordation of Patent Grant Mailed
Critical
| 09 Mar, 2021 | US10940156 |
|
Patent Issue Date Used in PTA Calculation
Critical
| 09 Mar, 2021 | US10940156 |
|
Email Notification
Critical
| 18 Feb, 2021 | US10940156 |
|
Issue Notification Mailed
Critical
| 17 Feb, 2021 | US10940156 |
| Dispatch to FDC | 29 Jan, 2021 | US10940156 |
|
Mail Response to 312 Amendment (PTO-271)
Critical
| 18 Jan, 2021 | US10940156 |
|
Email Notification
Critical
| 18 Jan, 2021 | US10940156 |
|
Response to Amendment under Rule 312
Critical
| 13 Jan, 2021 | US10940156 |
|
Amendment after Notice of Allowance (Rule 312)
Critical
| 11 Jan, 2021 | US10940156 |
|
Application Is Considered Ready for Issue
Critical
| 04 Jan, 2021 | US10940156 |
|
Issue Fee Payment Received
Critical
| 18 Dec, 2020 | US10940156 |
|
Issue Fee Payment Verified
Critical
| 18 Dec, 2020 | US10940156 |
| Entity Status Set To Undiscounted (Initial Default Setting or Status Change) | 18 Dec, 2020 | US10940156 |
Sage Therap Drug Patents' Oppositions Filed in EPO
Sage Therap drug patents have faced multiple oppositions in the European Patent Office. The earliest opposition was filed on Jul 08, 2020, by Dr. Schön, Neymeyr & Partner Patentanwälte Mbb. This opposition was filed on patent number EP13740743A. Click below to reveal the latest opposition data.
| Application | Filing Date | Opposition Party | Legal Status |
|---|---|---|---|
 | |||
| EP13740743A | Jul, 2020 | Dr. Schön, Neymeyr & Partner Patentanwälte mbB | Granted and Under Opposition |
Sage Therap's Family Patents
Sage Therap Drug List
Given below is the complete list of Sage Therap's drugs and the patents protecting them.
1. Zulresso
Zulresso is protected by 8 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US10940156 | Neuroactive steroids, compositions, and uses thereof |
08 Mar, 2037
(11 years from now)
| Active |
| US10251894 | Anticonvulsant activity of steroids |
27 Nov, 2033
(8 years from now)
| Active |
| US10322139 | Neuroactive steroid formulations and methods of treating CNS disorders |
23 Jan, 2033
(7 years from now)
| Active |
| US10117951 | Sulfoalkyl ether cyclodextrin compositions |
13 Mar, 2029
(3 years from now)
| Active |
| US7635773 | Sulfoalkyl ether cyclodextrin compositions |
13 Mar, 2029
(3 years from now)
| Active |
| US8410077 | Sulfoalkyl ether cyclodextrin compositions |
13 Mar, 2029
(3 years from now)
| Active |
| US9200088 | Sulfoalkyl ether cyclodextrin compositions |
13 Mar, 2029
(3 years from now)
| Active |
| US9750822 | Sulfoalkyl ether cyclodextrin compositions |
13 Mar, 2029
(3 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Zulresso's drug page